Daniel W. Muehl
2017 - Clovis Oncology
In 2017, Daniel W. Muehl earned a total compensation of $1.9M as Senior VP of Finance, Principal Accounting Officer, and Principal Financial Officer at Clovis Oncology, a 20% increase compared to previous year.
Compensation breakdown
| Bonus | $222,500 |
|---|---|
| Option Awards | $758,766 |
| Salary | $367,500 |
| Stock Awards | $512,325 |
| Other | $15,376 |
| Total | $1,876,467 |
Muehl received $758.8K in option awards, accounting for 40% of the total pay in 2017.
Muehl also received $222.5K in bonus, $367.5K in salary, $512.3K in stock awards and $15.4K in other compensation.
Rankings
In 2017, Daniel W. Muehl's compensation ranked 5,811th out of 14,666 executives tracked by ExecPay. In other words, Muehl earned more than 60.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,811 out of 14,666 | 60th |
Division Manufacturing | 2,112 out of 5,770 | 63rd |
Major group Chemicals And Allied Products | 657 out of 2,074 | 68th |
Industry group Drugs | 506 out of 1,730 | 71st |
Industry Pharmaceutical Preparations | 401 out of 1,329 | 70th |
Source: SEC filing on April 27, 2018.
Muehl's colleagues
We found four more compensation records of executives who worked with Daniel W. Muehl at Clovis Oncology in 2017.
News
Clovis Oncology CEO Patrick Mahaffy's 2021 pay slips 18% to $2.6M
April 27, 2022
Clovis Oncology CEO Patrick Mahaffy's 2020 pay falls 53% to $3.2M
April 28, 2021
Clovis Oncology CEO Patrick Mahaffy's 2019 pay rises 10% to $6.9M
April 24, 2020
Clovis Oncology CEO Patrick Mahaffy's 2018 pay falls 28% to $6.3M
April 26, 2019